Literature DB >> 11043157

Adult care in phenylketonuria and hyperphenylalaninaemia: the relevance of neurological abnormalities.

D P Brenton1, J Pietz.   

Abstract

UNLABELLED: Neurological abnormalities in phenylketonuria were described before dietary treatment became possible. These included tremor, clumsiness, epilepsy, spastic paraparesis and occasionally extrapyramidal features. Neurological deterioration after childhood was recognised. Patients with neurological deterioration described recently have been late diagnosed or intellectually impaired or both. No early diagnosed patient who was well treated and of good intellectual outcome has yet shown neurological deterioration after stopping diet but it may happen.
CONCLUSION: The fascinating links between pathology, magnetic resonance imaging appearances, magnetic resonance spectroscopy results and clinical features are not yet clearly understood. Patients must understand the possible risks of stopping diet and make their choice. All patients need help, support and follow-up regardless of the choices they make over continuing diet.

Entities:  

Mesh:

Year:  2000        PMID: 11043157     DOI: 10.1007/pl00014373

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Characterization of tremor in phenylketonuric patients.

Authors:  Belén Pérez-Dueñas; Josep Valls-Solé; Emilio Fernández-Alvarez; Jaon Conill; Maria Antonio Vilaseca; Rafael Artuch; Jaume Campistol
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

2.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

3.  Generalized seizures aggravated by levetiracetam in an adult patient with phenylketonuria.

Authors:  Nese Dericioglu; Serap Saygi
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

4.  Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Authors:  Robin Lachmann
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

5.  Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time.

Authors:  Charlotte Dawson; Elaine Murphy; Charlé Maritz; Heidi Chan; Charlotte Ellerton; R H S Carpenter; Robin H Lachmann
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

6.  Parkinsonism in phenylketonuria: a consequence of dopamine depletion?

Authors:  Marieke Velema; Erik Boot; Marc Engelen; Carla Hollak
Journal:  JIMD Rep       Date:  2015-01-23

7.  Epilepsy and phenylketonuria: a case description and EEG-fMRI findings.

Authors:  Melania Guida; Ilaria Pesaresi; Serena Fabbri; Ferdinando Sartucci; Mirco Cosottini; Filippo Sean Giorgi
Journal:  Funct Neurol       Date:  2014 Jan-Mar

8.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

9.  Central precocious puberty in a 3 year-old girl with Phenylketonuria: a rare association?

Authors:  Laura Lucaccioni; Bernd C Schwahn; Malcolm Donaldson; Claudio Giacomozzi
Journal:  BMC Endocr Disord       Date:  2014-04-28       Impact factor: 2.763

10.  A systematic review of cognitive functioning in early treated adults with phenylketonuria.

Authors:  Denise Leonne Hofman; Claire Louise Champ; Clare Louise Lawton; Mick Henderson; Louise Dye
Journal:  Orphanet J Rare Dis       Date:  2018-08-30       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.